Roche / Genentech Clinical Trial Pipeline: 256 Active Trials, 92 Changes This Month

56 trials changed in the last 30 days: 0 stopped, 14 with notable changes, 42 with minor changes only.

Notable

IMAGINATION · Sefaxersen (RO7434656) · Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary completion pushed from Aug 31, 2026 to May 25, 2028

Also in this update: Trial sites reduced: 178 → 171 locations; Completion pushed from Mar 31, 2029 to Aug 31, 2029

Hoffmann-La RochePhase 3 NCT05797610 Registry history of NCT05797610 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Notable

Different Doses of RO7795081 With Placebo or Semaglutide · Type 2 Diabetes

Primary and study completion pushed from Nov 27, 2026 to Feb 5, 2028

Also in this update: Enrollment increased: 240 → 330 participants; Trial sites reduced: 50 → 46 locations

Hoffmann-La RochePhase 2 NCT07112872 Registry history of NCT07112872 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Notable

Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), · ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Primary completion pushed from Feb 19, 2027 to Apr 20, 2028

Also in this update: Enrollment closed, study ongoing; Trial sites reduced: 352 → 311 locations

Hoffmann-La RochePhase 3 NCT06065748 Registry history of NCT06065748 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Notable

STARTRK-NG · Entrectinib (Rxdx-101) in Children and · Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027

Hoffmann-La RochePhase 1/2 NCT02650401 Registry history of NCT02650401 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Notable

NOVA-BEAM · Subcutaneously Administered RO7845860 · Relapsing Multiple Sclerosis

Primary endpoint(s) modified

Hoffmann-La RochePhase 1 NCT07749157 Registry history of NCT07749157 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

SAkuraSun · Satralizumab · Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Primary endpoint(s) modified

Hoffmann-La RochePhase 3 NCT05199688 Registry history of NCT05199688 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Notable

IMvigor011 · Atezolizumab Versus Placebo as Adjuvant Therapy · High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Primary endpoint(s) modified

Also in this update: Results posted: Sep 28, 2026; Trial sites reduced: 148 → 141 locations

Hoffmann-La RochePhase 3 NCT04660344 Registry history of NCT04660344 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Notable

Vixarelimab · Moderate to Severe Active Ulcerative Colitis

Phase changed: Phase 1/2 → Phase 1

Also in this update: Trial completed

Genentech, Inc.Phase 1 NCT06693908 Registry history of NCT06693908 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Notable

ZUPREME-4 · Petrelintide · Overweight or Obesity and Type 2 Diabetes

Recruitment opened

Hoffmann-La RochePhase 3 NCT07843485 Registry history of NCT07843485 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Notable

ZUPREME-3 · Petrelintide · Overweight or Obesity

Recruitment opened

Also in this update: Trial sites expanded: 0 → 3 locations

Hoffmann-La RochePhase 3 NCT07843498 Registry history of NCT07843498 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Notable

ZUPREME-5 · Petrelintide · Overweight or Obesity and Established Cardiovascular Disease

Recruitment opened

Also in this update: Trial sites expanded: 0 → 3 locations

Hoffmann-La RochePhase 3 NCT07843472 Registry history of NCT07843472 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Notable

SONATA-MS · Non-interventional Study of Subcutaneous Ocrelizumab · Relapsing-Remitting Multiple Sclerosis

Recruitment opened

Hoffmann-La RocheNot specified NCT07827586 Registry history of NCT07827586 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Notable

Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy · Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Results posted: Oct 9, 2026

Hoffmann-La RochePhase 3 NCT03456063 Registry history of NCT03456063 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

Rollover Study of Alectinib · Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Results posted: Oct 9, 2026

Hoffmann-La RochePhase 3 NCT03194893 Registry history of NCT03194893 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Show 42 trials with minor changes only

Minor

Ametrine-2 · Induction Therapy With Afimkibart (Also Known as RO7790121) · Moderately to Severely Active Ulcerative Colitis

Enrollment closed, study ongoing

Also in this update: Trial sites reduced: 200 → 168 locations; Primary completion moved earlier from Jan 30, 2027 to Oct 29, 2026

Hoffmann-La RochePhase 3 NCT06588855 Registry history of NCT06588855 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

Glofitamab + Gemcitabine + Oxaliplatin in U.S. · Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Enrollment closed, study ongoing

Also in this update: Trial sites reduced: 18 → 9 locations

Hoffmann-La RochePhase 1 NCT06624085 Registry history of NCT06624085 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy · Lung Cancer [IMpower010]

Trial completed

Also in this update: Trial sites expanded: 155 → 216 locations; Study completion date changed from estimate of Aug 31, 2027 to Aug 26, 2026

Hoffmann-La RochePhase 3 NCT02486718 Registry history of NCT02486718 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

TRONTIER 1 · Trontinemab · Early Symptomatic Alzheimer's Disease

Enrollment closed, study ongoing

Also in this update: Primary and study completion moved earlier from Jun 7, 2028 to Feb 16, 2028; Final enrollment: 1101 participants (planned 800)

Hoffmann-La RochePhase 3 NCT07169578 Registry history of NCT07169578 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

TRONTIER 2 · Trontinemab · Early Symptomatic Alzheimer's Disease

Enrollment closed, study ongoing

Also in this update: Trial sites reduced: 150 → 147 locations; Primary and study completion moved earlier from Jun 7, 2028 to Feb 16, 2028

Hoffmann-La RochePhase 3 NCT07170150 Registry history of NCT07170150 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

SKYSCRAPER-02C · Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab · Untreated Extensive-Stage Small Cell Lung Cancer

Trial completed

Also in this update: Study completion date changed from estimate of Jun 30, 2026 to Nov 17, 2025

Hoffmann-La RochePhase 3 NCT04665856 Registry history of NCT04665856 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Minor

SKYSCRAPER-07 · Atezolizumab With or Without Tiragolumab · Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Trial completed

Also in this update: Primary completion date changed from estimate of Mar 31, 2027 to Jul 22, 2026

Hoffmann-La RochePhase 3 NCT04543617 Registry history of NCT04543617 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

BURGUNDY · Zifibancimig · Neovascular Age-related Macular Degeneration

Trial completed

Hoffmann-La RochePhase 1/2 NCT04567303 Registry history of NCT04567303 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

EndomERA · Giredestrant · Grade 1 Endometrial Cancer

Trial completed

Also in this update: Final enrollment: 33 participants (planned 30)

Hoffmann-La RochePhase 2 NCT05634499 Registry history of NCT05634499 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Polatuzumab in Real World Clinical Practice · Diffuse Large B-Cell Lymphoma

Enrollment closed, study ongoing

Hoffmann-La RocheNot specified NCT05954910 Registry history of NCT05954910 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration · Multiple Sclerosis

Enrollment closed, study ongoing

Also in this update: Trial sites reduced: 32 → 26 locations

Hoffmann-La RochePhase 1 NCT05704361 Registry history of NCT05704361 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Close2HER · Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Primary and study completion pushed from May 31, 2028 to Oct 31, 2028

Hoffmann-La RocheNot specified NCT07527741 Registry history of NCT07527741 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo · Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Primary completion pushed from Dec 31, 2027 to Jun 15, 2028

And 2 more changes in the last 30 days

Hoffmann-La RochePhase 3 NCT05296798 Registry history of NCT05296798 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk · Untreated Diffuse Large B-Cell Lymphoma

Primary completion pushed from Sep 24, 2024 to Oct 24, 2024

Hoffmann-La RochePhase 2 NCT04980222 Registry history of NCT04980222 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

RO7806881 in Healthy Participants

Primary and study completion pushed from Mar 1, 2027 to May 11, 2027

Hoffmann-La RochePhase 1 NCT07271693 Registry history of NCT07271693 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Primary completion pushed from Sep 4, 2026 to Nov 16, 2026

Also in this update: Completion pushed from Sep 6, 2026 to Nov 16, 2026

Genentech, Inc.Phase 1 NCT07144111 Registry history of NCT07144111 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Minor

Cielo · Satralizumab · Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Trial sites reduced: 77 → 56 locations

Hoffmann-La RochePhase 3 NCT05503264 Registry history of NCT05503264 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

AMETRINE-PEDS · Afimkibart (RO7790121) · Moderately to Severely Active Ulcerative Colitis

Trial sites expanded: 22 → 26 locations

Hoffmann-La RochePhase 3 NCT07158242 Registry history of NCT07158242 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

Krascendo 2 · Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin · Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Trial sites expanded: 280 → 288 locations

Hoffmann-La RochePhase 3 NCT06793215 Registry history of NCT06793215 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

BREnnA · RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine · Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Trial sites expanded: 186 → 206 locations

Hoffmann-La RochePhase 2/3 NCT07413939 Registry history of NCT07413939 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

Kirros · Atezolizumab, With or Without Bevacizumab, · Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

Trial sites reduced: 59 → 54 locations

Genentech, Inc.Phase 2 NCT06096779 Registry history of NCT06096779 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

ZEBRHA 2 · NXT007 Compared to Emicizumab Prophylaxis · Hemophilia A

Trial sites expanded: 42 → 59 locations

Hoffmann-La RochePhase 3 NCT07416604 Registry history of NCT07416604 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

SIBERITE-PEDS · Afimkibart for Induction and Maintenance Therapy · Moderately to Severely Active Crohn's Disease

Trial sites expanded: 14 → 17 locations

Hoffmann-La RochePhase 3 NCT07298421 Registry history of NCT07298421 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

Mintaka · RO7268489 as Add-on Therapy to Ocrelizumab, · Progressive Forms of Multiple Sclerosis (MS)

Trial sites expanded: 108 → 114 locations

Hoffmann-La RochePhase 2 NCT07282574 Registry history of NCT07282574 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Minor

MoonROSE · GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant · Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Trial sites expanded: 64 → 74 locations

Genentech, Inc.Phase 1/2 NCT07100106 Registry history of NCT07100106 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

UmbrellaMAX · Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Trial sites expanded: 73 → 77 locations

Hoffmann-La RochePhase 3 NCT05862285 Registry history of NCT05862285 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

SIBERITE-2 · Induction Therapy With Afimkibart (RO7790121) · Moderately to Severely Active Crohn's Disease

Trial sites expanded: 199 → 203 locations

Hoffmann-La RochePhase 3 NCT06819891 Registry history of NCT06819891 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

ZEBRHA 1 · NXT007 Compared to Factor VIII Prophylaxis · Hemophilia A

Trial sites expanded: 27 → 32 locations

Hoffmann-La RochePhase 3 NCT07416526 Registry history of NCT07416526 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

TRAVELLER · Screening Study to Determine · Potential Trial Eligibility for Alzheimer's Disease Studies

Trial sites expanded: 212 → 229 locations

Hoffmann-La RochePhase 3 NCT07177352 Registry history of NCT07177352 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

Enith2 · Enicepatide (RO7795068) · Obesity or Overweight and Type 2 Diabetes

Trial sites expanded: 193 → 204 locations

Hoffmann-La RochePhase 3 NCT07351058 Registry history of NCT07351058 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Ametrine-1 · Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy · Moderately to Severely Active Ulcerative Colitis

Trial sites reduced: 200 → 184 locations

Hoffmann-La RochePhase 3 NCT06589986 Registry history of NCT06589986 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Enith1 · Enicepatide (RO7795068) · Obesity or Overweight Without Type 2 Diabetes

Trial sites expanded: 195 → 203 locations

Hoffmann-La RochePhase 3 NCT07351045 Registry history of NCT07351045 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Brainshuttle AD · RO7126209 Following Intravenous Infusion · Prodromal or Mild to Moderate Alzheimer's Disease

Trial sites reduced: 41 → 37 locations

Hoffmann-La RochePhase 1/2 NCT04639050 Registry history of NCT04639050 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

RO7673396 · Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Trial sites expanded: 21 → 25 locations

Hoffmann-La RochePhase 1 NCT06884618 Registry history of NCT06884618 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Primary and study completion moved earlier from Dec 31, 2026 to Nov 30, 2026

Hoffmann-La RochePhase 3 NCT03148418 Registry history of NCT03148418 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

RO7790121 · Advanced MASH Liver Fibrosis

Final enrollment: 56 participants (planned 50)

Hoffmann-La RochePhase 1 NCT06903065 Registry history of NCT06903065 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

CEA-PRIT 2.0 · Metastatic Colorectal Cancer (mCRC)

Start date pushed from Sep 8, 2026 to Oct 6, 2026

Hoffmann-La RochePhase 1 NCT07416552 Registry history of NCT07416552 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

MUSETTE · Higher Dose of Ocrelizumab · Relapsing Multiple Sclerosis (RMS)

Completion moved earlier from Aug 31, 2028 to Feb 21, 2028

Hoffmann-La RochePhase 3 NCT04544436 Registry history of NCT04544436 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

FENtrepid · Fenebrutinib Compared With Ocrelizumab · Primary Progressive Multiple Sclerosis

Completion pushed from Feb 28, 2027 to Jul 21, 2027

Hoffmann-La RochePhase 3 NCT04544449 Registry history of NCT04544449 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026
Minor

FENopta · Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Completion pushed from Dec 26, 2026 to Jun 30, 2027

Hoffmann-La RochePhase 2 NCT05119569 Registry history of NCT05119569 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

Ocrelizumab in Children and · Relapsing-Remitting Multiple Sclerosis

Completion pushed from Dec 1, 2029 to Apr 26, 2032

Hoffmann-La RochePhase 2 NCT04075266 Registry history of NCT04075266 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

ERY974 · Hepatocellular Carcinoma

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting

Chugai PharmaceuticalPhase 1 NCT05022927 Registry history of NCT05022927 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Phase	Status
2026-10-09	NCT07867262 A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant…	Phase 1	Not Yet Recruiting
2026-10-05	NCT07859085 A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in…	Phase 1	Not Yet Recruiting
2026-10-01	NCT07851259 A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic…	Phase 2	Not Yet Recruiting
2026-09-29	NCT07846683 A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in…	Phase 3	Not Yet Recruiting
2026-09-28	NCT07843472 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants…	Phase 3	Recruiting
2026-09-28	NCT07843485 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants…	Phase 3	Recruiting
2026-09-28	NCT07843498 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants…	Phase 3	Recruiting
2026-09-24	NCT07838194 Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and…	Phase 3	Not Yet Recruiting
2026-09-22	NCT07835243 A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of…	Phase 1	Not Yet Recruiting
2026-09-18	NCT07827573 A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer…	Phase 3	Not Yet Recruiting

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT06274515	A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies	Breast Cancer	Recruiting	2026-10-06
NCT04853251	A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related…	Neovascular Age-related Macular Degeneration	Recruiting	2026-10-02
NCT05861986	A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early…	Muscular Atrophy, Spinal	Recruiting	2026-10-02
NCT07609719	A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple…	Multiple Sclerosis	Recruiting	2026-09-30
NCT05861999	A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric…	Muscular Atrophy, Spinal	Recruiting	2026-09-10
NCT07483450	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of…	Relapsing Multiple Sclerosis	Active, Not Recruiting	2026-09-30
NCT05232929	Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)	Spinal Muscular Atrophy	Active, Not Recruiting	2026-09-09
NCT05224102	A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented…	Diabetic Macular Edema	Active, Not Recruiting	2026-08-25
NCT06795048	A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants…	Neovascular Age-related Macular Degeneration (nAMD)	Active, Not Recruiting	2026-07-31
NCT05181618	A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants…	Severe Hemophilia A	Active, Not Recruiting	2026-07-27
Phase 3
NCT06998524	A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von…	Von Willebrand Disease, Type 3	Recruiting	2026-10-09
NCT07177352	Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's…	Alzheimers Disease	Recruiting	2026-10-09
NCT07541079	A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant…	Early Breast Cancer	Recruiting	2026-10-09
NCT07670416	A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or…	Obesity	Recruiting	2026-10-08
NCT07843472	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants…	Obesity or Overweight	Recruiting	2026-10-07
NCT07843485	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants…	Obesity or Overweight	Recruiting	2026-10-07
NCT07843498	A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants…	Obesity or Overweight	Recruiting	2026-10-07
NCT06084936	A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in…	Lymphoma	Recruiting	2026-10-06
NCT06790693	A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and…	Breast Cancer	Recruiting	2026-10-06
NCT06793215	A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus…	Non-Small Cell Lung Cancer	Recruiting	2026-10-06
NCT07158242	A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121)…	Moderately to Severely Active Ulcerative Colitis	Recruiting	2026-10-06
NCT07174310	A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in…	Parkinson's Disease	Recruiting	2026-10-06
NCT07298421	A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for…	Moderately to Severely Active Crohns Disease	Recruiting	2026-10-06
NCT07416604	A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in…	Hemophilia A	Recruiting	2026-10-06
NCT05862285	A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La…	Cancer	Recruiting	2026-10-02

Roche / Genentech clinical trial pipeline

What changed in the last 30 days

New trial filings, last 30 days

Active trials by phase

Active trials top 25 of 256

Disease areas by active trials, top 10 of 47